In rheumatoid arthritis patients, tofacitinib - a novel oral medication was found to inhibit the progression of joint damage, show clinical trial results. Results of the 12-month interim analysis of the efficacy of tofacitinib appear in iArthritis (and) Rheumatism/i, a journal published by Wiley on behalf of the American College of Rheumatology (ACR). RA is a chronic, autoimmune disease that causes inflammation, pain and swelling of the joints. ...Thursday 24 January 2013
New Drug Slows Rheumatoid Arthritis Joint Damage
In rheumatoid arthritis patients, tofacitinib - a novel oral medication was found to inhibit the progression of joint damage, show clinical trial results. Results of the 12-month interim analysis of the efficacy of tofacitinib appear in iArthritis (and) Rheumatism/i, a journal published by Wiley on behalf of the American College of Rheumatology (ACR). RA is a chronic, autoimmune disease that causes inflammation, pain and swelling of the joints. ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment